drugset / Trial / NCT02289248

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

NCT02289248

Phase 1 Completed 16 enrolled Yale University
NaSingle-groupOpen-labelTreatment

Summary

Subjects with depressive episodes will be recruited to undergo a brief 2 week course of IV infusions of ketamine in combination with cognitive behavioral therapy for 8 weeks.

Timeline

Start
2015-02
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule Intravenous

Indications